Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 636

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 636
---
 137,500 |
| Wallace Hall  |     |             — |
| Jamie McNab   |     |             — |
| Michael Wyzga |     |       137,500 |
| Shaheen Wirk  |     |        15,000 |

| (3) | Amounts shown represent $10,000 paid to Mr. Wirk in the fiscal year ended 2024 pursuant to a consulting agreement by and between Tvardi and Mr. Wirk, dated January 21, 2021, for certain advisory services to be provided to Tvardi. |

352

<div align='center'>RELATED PERSON TRANSACTIONS OF THE COMBINED COMPANY</div>

Cara Related Party Transactions

Support Agreements

Concurrently with the execution of the Merger Agreement, the officers and directors of Cara, and their affiliated funds that hold Cara common stock and who collectively own approximately 1% of the outstanding shares of Cara common stock, entered into the Cara Support Agreements in favor of Tvardi relating to the Merger. The Cara Support Agreements provide, among other things, that such officers, directors and stockholders will vote all of their shares of Cara common stock: (i) in favor of adopting the Merger Agreement and approving the Merger, the other Contemplated Transactions and the Cara Proposals, (ii) against any proposal made in opposition to, or in competition with, the Merger Agreement or the Merger and (iii) against any Acquisition Proposal

Lock-Up Agreements

Concurrently with the execution of the Merger Agreement, the director of Cara designated prior to Closing to serve on the Combined Company Board is expected to enter into a Lock-Up Agreement.

Transactions With Vifor (International) Ltd.

Vifor Pharma License Agreement

In October 2020, Cara entered into a license agreement (Vifor Pharma Agreement) with Vifor (International) Ltd. (Vifor Pharma), under which Cara granted Vifor Pharma an exclusive license solely in the United States to use, distribute, offer for sale, promote, sell and otherwise commercialize Cara’s product candidate KORSUVA injection for all therapeutic uses relating to the inhibition, prevention or treatment of itch associated with pruritus in hemodialysis and peritoneal dialysis patients in the United States. Under the Vifor Pharma Agreement, Cara retains all rights with respect to the clinical development of, and activities to gain regulatory approvals of, KORSUVA injection in the United